Carlos is the former CEO of Immune Design Corp., a late-stage Immunotherapy company which was acquired by Merck & Co. in April 2019. He previously served as President of Elan Pharmaceuticals, and spent a number of years with Eli Lilly and Co. in discovery research and clinical development leadership roles, including Global Leader of the diabetes and endocrine franchise. Prior to his industry roles, Carlos spent nearly a decade at the Mayo Clinic (Rochester) where his roles included Professor of Medicine, Immunology and Pathology, and Vice Dean of the clinical investigation program. He commenced his career as a research scientist at Institute Pasteur in Paris. Carlos is a Non-Executive Director on the boards of Mallinckrodt, Highlight Therapeutics and Fluidigm. MD and PhD, Madrid Medical School (Complutense); Internal Medicine, Infectious Diseases, Immunology speciality training, Mayo Graduate School of Medicine
